Evaluation of safety and immunogenicity of receptor-binding domain-based COVID-19 vaccine (Corbevax) to select the optimum formulation in open-label, multicentre, and randomised phase-1/2 and phase-2 clinical trials

Autor: Thuluva, Subhash ^{a, ⁎}, Paradkar, Vikram ^a, Gunneri, Subba Reddy ^a, Yerroju, Vijay ^a, Mogulla, Rammohan ^a, Turaga, Kishore ^a, Kyasani, Mahesh ^a, Manoharan, Senthil Kumar ^a, Medigeshi, Guruprasad ^b, Singh, Janmejay ^b, Shaman, Heena ^b, Singh, Chandramani ^c, Rao A, Venkateshwar ^d

Publikováno v: In eBioMedicine September 2022 83

Immunogenicity and safety of Biological E's CORBEVAX™ vaccine compared to COVISHIELD™ (ChAdOx1 nCoV-19) vaccine studied in a phase-3, single blind, multicentre, randomized clinical trial.

Autor: Thuluva, Subhash, Paradkar, Vikram, Gunneri, SubbaReddy, Yerroju, Vijay, Mogulla, Rammohan, Suneetha, Pothakamuri Venkata, Turaga, Kishore, Kyasani, Mahesh, Manoharan, Senthil Kumar, Adabala, Srikanth, Sri Javvadi, Aditya, Medigeshi, Guruprasad, Singh, Janmejay, Shaman, Heena, Binayke, Akshay, Zaheer, Aymaan, Awasthi, Amit, Singh, Chandramani, Rao A, Venkateshwar, Basu, Indranil

Publikováno v: Human Vaccines & Immunotherapeutics; 2023, Vol. 19 Issue 1, p1-11, 11p

Personal Authentication Using Multifeatures Multispectral Palm Print Traits.

Autor: Rajagopal G; Department of Electronics and Communication Engineering, Sri Venkateswara College of Engineering, Sriperumbudur Taluk, Tamil Nadu 602117, India., Manoharan SK; Department of Electronics and Communication Engineering, Sri Venkateswara College of Engineering, Sriperumbudur Taluk, Tamil Nadu 602117, India.

Publikováno v: TheScientificWorldJournal [ScientificWorldJournal] 2015; Vol. 2015, pp. 861629. Date of Electronic Publication: 2015 Jun 14.